AQP1 and breast carcinoma: In the AQP1 high expression group, both OS and PFS (OS: P = 0.033, PFS: P = 0.001) of breast cancer patients treated with CEF regimens were significantly longer than those with non-CEF regimens, and patients with low AQP1 expression could not benefit from CEF regimens (Fig. 1e).